Stark W J, Fagadau W R, Stewart R H, Crandall A S, deFaller J M, Reaves T A, Klein P E
Arch Ophthalmol. 1986 Mar;104(3):364-6. doi: 10.1001/archopht.1986.01050150064027.
The efficacy of a new nonsteroidal anti-inflammatory agent, suprofen, for reducing pupillary constriction during cataract surgery was ascertained in a double-masked, multicenter, clinical study. Prior to surgery 1.0% suprofen or a placebo was instilled; the surgeon's normal regimen of mydriatics and cycloplegics was used. Suprofen (209 patients) was far more effective than the placebo (203 patients) in maintaining a dilated pupil prior to intraocular lens (IOL) implantation (or instillation of a miotic). The mean pupillary area prior to IOL implantation was 6.3 sq mm larger (20% larger) in patients treated with suprofen than in patients receiving the placebo. The investigators' subjective evaluations of the adequacy of pupil size for IOL implantation and of the difficulty of IOL implantation favored patients treated with suprofen over those receiving the placebo.
在一项双盲、多中心临床研究中,确定了一种新型非甾体抗炎药舒洛芬在白内障手术期间减少瞳孔收缩方面的疗效。手术前滴入1.0%舒洛芬或安慰剂;使用外科医生常规的散瞳药和睫状肌麻痹药。在植入人工晶状体(IOL)(或滴入缩瞳剂)之前,舒洛芬组(209例患者)在维持瞳孔散大方面远比安慰剂组(203例患者)有效。植入IOL前,舒洛芬治疗患者的平均瞳孔面积比接受安慰剂治疗的患者大6.3平方毫米(大20%)。研究者对IOL植入时瞳孔大小是否合适以及IOL植入难度的主观评估表明,舒洛芬治疗的患者优于接受安慰剂治疗的患者。